tbuckley/cabot-search huggingface dataset:
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
Authors: Hans Jaeger, Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Jaime Federico Andrade-Villanueva, Rosie Mngqibisa, Antonio Ocampo Hermida, Anders Thalme, Elena Belonosova, Faïza Ajana, Paul D Benn, Yuanyuan Wang, Krischan J Hudson, Carlos Martín Español, Susan L Ford, Herta Crauwels, David A Margolis, Christine L Talarico, Kimberly Y Smith, Veerle van Eygen, Rodica Van Solingen-Ristea, Simon Vanveggel, William R Spreen
Journal: The Lancet HIV (2021)
Structural Racism and Pediatric Health—A Call for Research to Confront the Origins of Racial Disparities in Health
Authors: Natalie Slopen, Nia Heard-Garris
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Walking on common ground: a cross-disciplinary scoping review on the clinical utility of digital mobility outcomes
Authors: Ashley Polhemus, Laura Delgado-Ortiz, Gavin Brittain, Nikolaos Chynkiamis, Francesca Salis, Heiko Gaßner, Michaela Gross, Cameron Kirk, Rachele Rossanigo, Kristin Taraldsen, Diletta Balta, Sofie Breuls, Sara Buttery, Gabriela Cardenas, Christoph Endress, Julia Gugenhan, Alison Keogh, Felix Kluge, Sarah Koch, M. Encarna Micó-Amigo, Corinna Nerz, Chloé Sieber, Parris Williams, Ronny Bergquist, Magda Bosch de Basea, Ellen Buckley, Clint Hansen, A. Stefanie Mikolaizak, Lars Schwickert, Kirsty Scott, Sabine Stallforth, Janet van Uem, Beatrix Vereijken, Andrea Cereatti, Heleen Demeyer, Nicholas Hopkinson, Walter Maetzler, Thierry Troosters, Ioannis Vogiatzis, Alison Yarnall, Clemens Becker, Judith Garcia-Aymerich, Letizia Leocani, Claudia Mazzà, Lynn Rochester, Basil Sharrack, Anja Frei, Milo Puhan
Journal: npj Digital Medicine (2021)

Abstract Physical mobility is essential to health, and patients often rate it as a high-priority clinical outcome. Digital mobility outcomes (DMOs), such as real-world gait speed or step count, show promise as clinical measures in many medical conditions. However, current research is nascent and fragmented by discipline. This scoping review maps existing evidence on the clinical utility of DMOs, identifying commonalities across traditional disciplinary divides. In November 2019, 11 databases were searched for records investigating the validity and responsiveness of 34 DMOs in four diverse medical conditions (Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease, hip fracture). Searches yielded 19,672 unique records. After screening, 855 records representing 775 studies were included and charted in systematic maps. Studies frequently investigated gait speed (70.4% of studies), step length (30.7%), cadence (21.4%), and daily step count (20.7%). They studied differences between healthy and pathological gait (36.4%), associations between DMOs and clinical measures (48.8%) or outcomes (4.3%), and responsiveness to interventions (26.8%). Gait speed, step length, cadence, step time and step count exhibited consistent evidence of validity and responsiveness in multiple conditions, although the evidence was inconsistent or lacking for other DMOs. If DMOs are to be adopted as mainstream tools, further work is needed to establish their predictive validity, responsiveness, and ecological validity. Cross-disciplinary efforts to align methodology and validate DMOs may facilitate their adoption into clinical practice.
Tachycardia-Dependent Paroxysmal Atrioventricular Block—Reply
Authors: Matthew C. Hyman, David S. Frankel
Journal: JAMA Internal Medicine (2021)

In Reply We appreciate the comments from Dr Littmann regarding our case report on paroxysmal atrioventricular (AV) block.1 His letter highlights heterogeneity in the use of the term paroxysmal AV block.
Abstract 16889: A Novel Single-Chain Enzyme Complex With Triple-Catalytic Activities Controlling the Metabolism of Arachidonic Acid Toward the Anti-Bleeding Thromboxane A2 Biosynthesis
Authors: Yan Li, Qunying Li, Qinglan Ling, Chang Chen, Ke-He Ruan
Journal: Circulation (2018)

Background: One of the most common bleeding emergencies in interventional cardiology and surgical procedures is caused by the use of nonsteroidal anti-inflammatory drugs (NSAIDs), which strongly in...
Abstract 11448: Associations of Irs-1 Genetic Polymorphism With the State of Vascular Wall and the Severity of Insulin Resistance in Hypertensive Patients Without Type 2 Diabetes
Authors: Anna Shalimova, Galyna Fadieienko, Olena Kolesnikova
Journal: Circulation (2019)

Introduction: It is known that insulin receptor substrate-1 (IRS-1) gene polymorphism is associated with the development type 2 diabetes (DM2). However, it is not clear how it affects insulin resis...
6P Circulating tumor DNA (ctDNA) next generation sequencing (NGS): Molecular prescreening for tailoring treatment in clinical trials
Authors: G. Alonso, S. Aguilar, F.J. Ros Montana, H. Verdaguer, A. Callejo Perez, I. Brana, I. Baraibar Argota, P. Iranzo Gomez, O. Saavedra Santa Gadea, F. Salva Ballabrera, D.A. Acosta Eyzaguirre, M. Vieito Villar, E. Garcia Torralba, N.A. Wornham, I. Faull, J. Tabernero, E. Felip, E. Elez, T. Macarulla Mercade, E. Garralda
Journal: Annals of Oncology (2021)
Abstract 546: Postconditioning Fails to Limit Infarct Size in the Setting of Type-2 and Type-1 Diabetes
Authors: Karin Przyklenk, Michelle Maynard, Craig S Smith, Peter Whittaker
Journal: Circulation (2007)

Relief of ischemia in a stuttering manner (postconditioning: PostC) has been shown to limit infarct size, due in part to activation of ERK 1/2 during the early minutes of reflow. However, it is unknown whether the efficacy of PostC is maintained in the setting of clinically relevant co-morbidities such as diabetes. To address this issue, isolated buffer-perfused hearts were obtained from: healthy adult C57BL/6J mice (mean blood glucose [mg/dL]: 178±7); age-matched BKS.Cg-m+/+ Lepr db /J mice (genetic model model of type-2 diabetes; hyper-glycemic with blood glucose of 480±23); and adult C57 mice injected 2 weeks previously with streptozotocin (model of type-1 diabetes; blood glucose: 556±15). All hearts underwent 30 min global ischemia and received either: complete, abrupt reperfusion (controls); PostC with 3 10-sec cycles of stuttered reflow; or an amplified (6 cycle) PostC stimulus. Experiments were conducted with both standard perfusate and fatty acid-supplemented buffer (1.5 mM palmitate). In hearts from healthy mice, PostC: was cardioprotective (infarct size [delineated by tetrazolium staining] was 27±3% and 29±5% of the LV in PostC groups vs 50±3% in controls; p&lt;.05); and was associated with an up-regulation of ERK signaling (including significant, &gt;2-fold increases in expression of phospho-ERK and downstream targets of ERK [i.e., p70S6-kinase phosphorylated at Thr421/Ser424]). Similar data were obtained, irrespective of the presence or absence of palmitate in the buffer. Moreover, the infarct-sparing effect of PostC was blocked by the ERK inhibitor PD98059 (infarct size: 68±7% vs 63±4% in PD-treated PostC vs control groups), consistent with a requisite role of ERK signaling in PostC-induced protection. In contrast, in the type-2 diabetic model, PostC did not activate ERK signaling and exacerbated (rather than reduced) infarct size (57±3%, 61±3% and 74±4%* in control, 3- and 6-cycle PostC groups; *p&lt;.05 vs control) – outcomes that were not mitigated by addition of palmitate to the buffer. Similar loss of PostC-induced protection was seen with type-1 diabetes. Thus, PostC fails to reduce infarct size in the setting of both type-2 and type-1 diabetes, possibly due to impaired up-regulation of ERK signaling.
Prognostic Impact of the Histologic Lepidic Component in Pathologic Stage IA Adenocarcinoma
Authors: Yu Okubo, Jumpei Kashima, Takashi Teishikata, Yuji Muraoka, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Hirokazu Watanabe, Masahiko Kusumoto, Shun-Ichi Watanabe, Yasushi Yatabe
Journal: Journal of Thoracic Oncology (2021)
Fungal biomarker testing turn-around-times at the UK National Mycology Reference Laboratory: Setting the record straight
Authors: Andrew M Borman, Mark Fraser, Zoe Patterson, Sue McLachlan, Michael D Palmer, Ciara Mann, Debra Oliver, Phillipa Brown, Christopher J Linton, Agnieszka Dzietczyk, Michelle Hedley, Martin Gough, Lydia Zapata, Paul North, Elizabeth M Johnson
Journal: Journal of Infection (2021)
Biblical and theological opposition to assisted dying
Authors: Gavriel Cohn
Journal: BMJ (2021)

In their essay on the support of religious people and leaders for assisted dying, Romain and Carey use terms that empty assisted dying of any connotations other than being a medical procedure.1 Yet there is no reason to medicalise or sanitise it. Doctors should also not have the final say in legislation.

The authors claim that “there is nothing in our bibles or …
Wirelessly operated bioelectronic sutures for the monitoring of deep surgical wounds
Authors: Viveka Kalidasan, Xin Yang, Ze Xiong, Renee R. Li, Haicheng Yao, Hareesh Godaba, Sybil Obuobi, Priti Singh, Xin Guan, Xi Tian, Selman A. Kurt, Zhipeng Li, Devika Mukherjee, Ravisankar Rajarethinam, Choon Seng Chong, Jiong-Wei Wang, Pui Lai Rachel Ee, Weiqiang Loke, Benjamin C. K. Tee, Jianyong Ouyang, Christopher J. Charles, John S. Ho
Journal: Nature Biomedical Engineering (2021)
Preload Stress Echocardiography for the Assessment of Heart Failure With Preserved Ejection Fraction
Authors: Kenya Kusunose, Hirotsugu Yamada, Yoshihito Saijo, Susumu Nishio, Yukina Hirata, Takayuki Ise, Koji Yamaguchi, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Tetsuzo Wakatsuki, Masataka Sata
Journal: JACC. Cardiovascular imaging (2021)
Epicardial adipose tissue volume is greater in men with severe psoriasis, implying an increased cardiovascular disease risk: A cross-sectional study
Authors: Charles N. Ellis, Stephen J. Neville, Mohamed Sayyouh, James T. Elder, Rajan P. Nair, Johann E. Gudjonsson, Tianwen Ma, Ella A. Kazerooni, Melvyn Rubenfire, Prachi P. Agarwal
Journal: Journal of the American Academy of Dermatology (2021)
Pannexin 1: a novel regulator of acute hypoxic pulmonary vasoconstriction
Authors: Benjamin Grimmer, Adrienn Krauszman, Xudong Hu, Golam Kabir, Kim A Connelly, Mei Li, Jana Grune, Christian Madry, Brant E Isakson, Wolfgang M Kuebler
Journal: Cardiovascular Research (2021)

Abstract Aims Hypoxic pulmonary vasoconstriction (HPV) is a physiological response to alveolar hypoxia that diverts blood flow from poorly ventilated to better aerated lung areas to optimize ventilation-perfusion matching. Yet, the exact sensory and signalling mechanisms by which hypoxia triggers pulmonary vasoconstriction remain incompletely understood. Recently, ATP release via pannexin 1 (Panx1) and subsequent signalling via purinergic P2Y receptors has been identified as regulator of vasoconstriction in systemic arterioles. Here, we probed for the role of Panx1-mediated ATP release in HPV and chronic hypoxic pulmonary hypertension (PH). Methods and results Pharmacological inhibition of Panx1 by probenecid, spironolactone, the Panx1 specific inhibitory peptide (10Panx1), and genetic deletion of Panx1 specifically in smooth muscle attenuated HPV in isolated perfused mouse lungs. In pulmonary artery smooth muscle cells (PASMCs), both spironolactone and 10Panx1 attenuated the increase in intracellular Ca2+ concentration ([Ca2+]i) in response to hypoxia. Yet, genetic deletion of Panx1 in either endothelial or smooth muscle cells did not prevent the development of PH in mice. Unexpectedly, ATP release in response to hypoxia was not detectable in PASMC, and inhibition of purinergic receptors or ATP degradation by ATPase failed to attenuate HPV. Rather, transient receptor potential vanilloid 4 (TRPV4) antagonism and Panx1 inhibition inhibited the hypoxia-induced [Ca2+]i increase in PASMC in an additive manner, suggesting that Panx1 regulates [Ca2+]i independently of the ATP-P2Y-TRPV4 pathway. In line with this notion, Panx1 overexpression increased the [Ca2+]i response to hypoxia in HeLa cells. Conclusion In the present study, we identify Panx1 as novel regulator of HPV. Yet, the role of Panx1 in HPV was not attributable to ATP release and downstream signalling via P2Y receptors or TRPV4 activation, but relates to a role of Panx1 as direct or indirect modulator of the PASMC Ca2+ response to hypoxia. Panx1 did not affect the development of chronic hypoxic PH.
Implantable vs Prolonged External Electrocardiographic Monitoring for Atrial Fibrillation Detection in Patients With Ischemic Stroke
Authors: Hiroshi Ito
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Integrating single-cell genomics pipelines to discover mechanisms of stem cell differentiation
Authors: Sophie Shen, Yuliangzi Sun, Maika Matsumoto, Woo Jun Shim, Enakshi Sinniah, Sean B. Wilson, Tessa Werner, Zhixuan Wu, Stephen T. Bradford, James Hudson, Melissa H. Little, Joseph Powell, Quan Nguyen, Nathan J. Palpant
Journal: Trends in Molecular Medicine (2021)
GPs move towards industrial action after rejecting “rescue plan” for general practice
Authors: Abi Rimmer
Journal: BMJ (2021)

The BMA’s England GP committee (GPC) is seeking approval to ballot GPs on industrial action that could constitute a breach of contract.

The move comes after the committee formally rejected the health secretary’s rescue package for general practice.

Sajid Javid’s plan pledged an extra £250m (€296m; $345m) to increase the proportion of appointments that practices deliver face-to-face, which will require local commissioners to identify the 20% of practices in their area with the lowest levels of such appointments.1

At a meeting on 21 October, however, GPC members passed a motion that rejected the plan. This comes after the majority (93%) of 3500 GPs in …
BEVACIZUMAB-INDUCED HYPERTENSION IS A PREDICTIVE MARKER OF RESPONSE AND PROGRESSION FREE SURVIVAL IN PATIENTS TREATED FOR METASTATIC COLORECTAL CANCER
Authors: A. De Stefano, C. Carlomagno, L. Cannella, A. Crispo, Stefano Pepe, S. Alfieri, M. Colantuoni, C. Cella, L. Raimondo, S. De Placido
Journal: Annals of Oncology (2009)
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
Authors: S. Georgin‐Lavialle, B. Terrier, A.F. Guedon, M. Heiblig, T. Comont, E. Lazaro, V. Lacombe, L. Terriou, S. Ardois, J.‐D. Bouaziz, A. Mathian, G. Le Guenno, A. Aouba, R. Outh, A. Meyer, M. Roux‐Sauvat, M. Ebbo, L.P. Zhao, A. Bigot, Y. Jamilloux, V. Guillotin, E. Flamarion, P. Henneton, G. Vial, V. Jachiet, J. Rossignol, S. Vinzio, T. Weitten, J. Vinit, C. Deligny, S. Humbert, M. Samson, N. Magy‐Bertrand, T. Moulinet, R. Bourguiba, T. Hanslik, C. Bachmeyer, M. Sebert, M. Kostine, B. Bienvenu, P. Biscay, E. Liozon, L. Sailler, F. Chasset, A. Audemard‐Verger, E. Duroyon, G. Sarrabay, F. Borlot, C. Dieval, T. Cluzeau, P. Marianetti, H. Lobbes, G. Boursier, M. Gerfaud‐Valentin, J. Jeannel, A. Servettaz, S. Audia, M. Larue, B. Henriot, B. Faucher, J. Graveleau, B. de Sainte Marie, J. Galland, L. Bouillet, C. Arnaud, L. Ades, F. Carrat, P. Hirsch, P. Fenaux, O. Fain, P. Sujobert, O. Kosmider, A. Mekinian
Journal: British Journal of Dermatology (2021)

A new autoinflammatory syndrome related to somatic mutations of UBA1 was recently described and called VEXAS syndrome ('Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome').To describe clinical characteristics, laboratory findings and outcomes of VEXAS syndrome.One hundred and sixteen patients with VEXAS syndrome were referred to a French multicentre registry between November 2020 and May 2021. The frequency and median of parameters and vital status, from diagnosis to the end of the follow-up, were recorded.The main clinical features of VEXAS syndrome were found to be skin lesions (83%), noninfectious fever (64%), weight loss (62%), lung involvement (50%), ocular symptoms (39%), relapsing chondritis (36%), venous thrombosis (35%), lymph nodes (34%) and arthralgia (27%). Haematological disease was present in 58 cases (50%): myelodysplastic syndrome (MDS; n = 58) and monoclonal gammopathy of unknown significance (n = 12; all patients with MGUS also have a MDS). UBA1 mutations included p.M41T (45%), p.M41V (30%), p.M41L (18%) and splice mutations (7%). After a median follow-up of 3 years, 18 patients died (15·5%; nine of infection and three due to MDS progression). Unsupervised analysis identified three clusters: cluster 1 (47%; mild-to-moderate disease); cluster 2 (16%; underlying MDS and higher mortality rates); and cluster 3 (37%; constitutional manifestations, higher C-reactive protein levels and less frequent chondritis). The 5-year probability of survival was 84·2% in cluster 1, 50·5% in cluster 2 and 89·6% in cluster 3. The UBA1 p.Met41Leu mutation was associated with a better prognosis.VEXAS syndrome has a large spectrum of organ manifestations and shows different clinical and prognostic profiles. It also raises a potential impact of the identified UBA1 mutation.
Subdiaphragmatic Lymph Nodes Uptake on 18F-FDG PET/CT After COVID-19 Vaccination in the Thigh
Authors: Elske Quak, Adeline Morel, Julie Faudemer, Christelle Levy, Renaud Ciappuccini
Journal: Clinical Nuclear Medicine (2021)

Abstract Since worldwide COVID-19 vaccination, 18 F-FDG uptake in reactive axillary lymph nodes has been frequently observed in PET/CT studies. We describe a patient with breast cancer who underwent 18 F-FDG PET/CT 7 days after receiving COVID-19 vaccination in the right thigh. 18 F-FDG uptake was observed in nonenlarged right-sided inguinal, iliac, and para-aortic lymph nodes. As the thigh can be used as an alternate site for COVID-19 vaccine injection in case of lymphedema in both arms or for adequate axillary staging in patients with breast cancer, physicians should be aware of such 18 F-FDG uptake pattern.
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Authors: Peter Valent, Cem Akin, Karin Hartmann, Ivan Alvarez-Twose, Knut Brockow, Olivier Hermine, Marek Niedoszytko, Juliana Schwaab, Jonathan J. Lyons, Melody C. Carter, Hanneke Oude Elberink, Joseph H. Butterfield, Tracy I. George, Georg Greiner, Celalettin Ustun, Patrizia Bonadonna, Karl Sotlar, Gunnar Nilsson, Mohamad Jawhar, Frank Siebenhaar, Sigurd Broesby-Olsen, Selim Yavuz, Roberta Zanotti, Magdalena Lange, Boguslaw Nedoszytko, Gregor Hoermann, Mariana Castells, Deepti H. Radia, Javier I. Muñoz-Gonzalez, Wolfgang R. Sperr, Massimo Triggiani, Hanneke C. Kluin-Nelemans, Stephen J. Galli, Lawrence B. Schwartz, Andreas Reiter, Alberto Orfao, Jason Gotlib, Michel Arock, Hans-Peter Horny, Dean D. Metcalfe
Journal: HemaSphere (2021)

Mastocytosis is a hematologic neoplasm characterized by expansion and focal accumulation of neoplastic mast cells (MC) in diverse organs, including the skin, bone marrow (BM), spleen, liver, and gastrointestinal tract. The World Health Organization classification divides the disease into prognostically distinct variants of cutaneous mastocytosis (CM) and systemic mastocytosis (SM). Although this classification remains valid, recent developments in the field and the advent of new diagnostic and prognostic parameters created a need to update and refine definitions and diagnostic criteria in MC neoplasms. In addition, MC activation syndromes (MCAS) and genetic features predisposing to SM and MCAS have been identified. To discuss these developments and refinements in the classification, we organized a Working Conference comprised of experts from Europe and the United States in August 2020. This article reports on outcomes from this conference. Of particular note, we propose adjustments in the classification of CM and SM, refinements in diagnostic criteria of SM variants, including smoldering SM and BM mastocytosis (BMM), and updated criteria for MCAS and other conditions involving MC. CD30 expression in MC now qualifies as a minor SM criterion, and BMM is now defined by SM criteria, absence of skin lesions and absence of B- and C-findings. A basal serum tryptase level exceeding 20 ng/mL remains a minor SM criterion, with recognition that hereditary alpha-tryptasemia and various myeloid neoplasms may also cause elevations in tryptase. Our updated proposal will support diagnostic evaluations and prognostication in daily practice and the conduct of clinical trials in MC disorders.
Exposure to inorganic particles in paediatric sarcoidosis: the PEDIASARC study
Authors: Nadia Nathan, Marie-Emeline Montagne, Odile Macchi, Paul-André Rosental, Simon Chauveau, Florence Jeny, Lucile Sesé, Rola Abou Taam, Manon Brocvielle, Jacques Brouard, Mickaël Catinon, Catherine Chapelon-Abric, Fleur Cohen-Aubart, Christophe Delacourt, Céline Delestrain, Antoine Deschildre, Antoine Dossier, Ralph Epaud, Julien Haroche, Véronique Houdouin, Dominique Israel-Biet, Karine Juvin, Sylvain Le Jeune, Francois Lionnet, Ulrich Meinzer, Marie Mittaine, Hilario Nunes, Sarah Mattioni, Jean-Marc Naccache, Marie-Hélène Odièvre, Michel Vincent, Annick Clement, Dominique Valeyre, Catherine Cavalin
Journal: Thorax (2021)

Inorganic antigens may contribute to paediatric sarcoidosis. Thirty-six patients matched with 36 healthy controls as well as a group of 21 sickle-cell disease (SCD) controls answered an environmental questionnaire. Patients’ indirect exposure to inorganic particles, through coresidents’ occupations, was higher than in healthy and SCD controls (median score: 2.5 (0.5–7) vs 0.5 (0–2), p=0.003 and 1 (0–2), p=0.012, respectively), especially for construction, exposures to metal dust, talc, abrasive reagents and scouring products. Wood or fossil energies heating were also linked to paediatric sarcoidosis. This study supports a link between mineral environmental exposure due to adult coresident occupations and paediatric sarcoidosis.